Europe in Situ Hybridization Market was worth USD 155 million in 2016 and estimated to be growing at a CAGR of 5.85%, to reach USD 206 million by 2021. The market is showcasing evident potential in the mentioned forecasting period. The market continues to gain momentum with the rapid development in the medical industry.
In situ hybridization (ISH) is a kind of hybridization that involves a labelled complementary DNA, RNA or modified nucleic acids strand to spot or localize a specific DNA or RNA sequence in a portion or part of tissue i.e. in situ. The major techniques presently include: in situ hybridization to mRNA with oligonucleotide and RNA probes; analysis with light and electron microscopes; whole mount in situ hybridization; double detection of RNAs and RNA plus protein; and fluorescent in situ hybridization to spot chromosomal sequences.
The growth of the overall in situ hybridization market can said to be driven by the growing diagnosis and increasing incidence of cancer, advancements in therapeutics technology, as well as rising government initiatives across the globe. Increased healthcare expenses are also responsible for the growth of this market.
Europe in situ hybridization market is segmented on the basis of Technique into FISH, and CISH. Based on Application, the market is segmented into Cancer Diagnosis, Neuroscience, Cytology, and Infectious Disease. On the basis of End User, the market is segmented into Molecular Diagnostic Laboratories, Academic and Research Institutions.
On the basis of geography, the Europe market is analysed under the regions namely U.K, Germany, France, Spain and Italy. The Europe In Situ Hybridization is expected to grow in the future years owing to the increased focus on R & D as well as growing healthcare expenditure.
Some of the major companies dominating the market, by their products are Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.)
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technique
5.1.1 Introduction
5.1.2 FISH
5.1.3 CISH
5.1.4 Y-o-Y Growth Analysis, By Technique
5.1.5 Market Attractiveness Analysis, By Technique
5.1.6 Market Share Analysis, By Technique
5.2 Application
5.2.1 Introduction
5.2.2 Cancer Diagnosis
5.2.3 Neuroscience
5.2.4 Cytology
5.2.5 Infectious Disease
5.2.6 Y-o-Y Growth Analysis, By Application
5.2.7 Market Attractiveness Analysis, By Application
5.2.8 Market Share Analysis, By Application
5.3 End User
5.3.1 Introduction
5.3.2 Molecular Diagnostic Laboratories
5.3.3 Academic And Research Institutions
5.3.4 Y-o-Y Growth Analysis, By End User
5.3.5 Market Attractiveness Analysis, By End User
5.3.6 Market Share Analysis, By End User
5.4 Type
5.4.1 Introduction
5.4.2 DNA
5.4.3 RNA
5.4.4 Y-o-Y Growth Analysis, By Type
5.4.5 Market Attractiveness Analysis, By Type
5.4.6 Market Share Analysis, By Type
5.5 Product
5.5.1 Introduction
5.5.2 Instruments
5.5.3 Probes & Kits
5.5.4 Y-o-Y Growth Analysis, By Type
5.5.5 Market Attractiveness Analysis, By Type
5.5.6 Market Share Analysis, By Type
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technique
6.1.3.3 By Application
6.1.3.4 By End User
6.1.3.5 By Type
6.1.3.6 By Product
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technique
6.1.4.3 By Application
6.1.4.4 By End User
6.1.4.5 By Type
6.1.4.6 By Product
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technique
6.1.5.3 By Application
6.1.5.4 By End User
6.1.5.5 By Type
6.1.5.6 By Product
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Laboratories, Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 F. Hoffmann-La Roche AG
8.3 Leica Biosystems Nussloch GmbH
8.4 Agilent Technologies
8.5 Thermo Fisher Scientific, Inc.
8.6 Merck KGaA
8.7 PerkinElmer, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
